Altre lingue UroGen Pharma Ltd.

Azioni

URGN

IL0011407140

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 18/04/2024			Variaz. 5gg	Var. 1 gen.
14,26 ^USD	+0,14%		+7,62%	-4,93%

15/04	UroGen Pharma dice che la FDA accetta la domanda di sperimentazione di un nuovo farmaco per un potenziale trattamento del cancro alla vescica	MT
15/03	UROGEN PHARMA LTD. : prospettiva positiva di Oppenheimer	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers	17/04
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	16/04
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	15/04
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer	15/04
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	03/04
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals	03/04
UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102	15/03
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102	14/03
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	11/03
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024	04/03
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference	26/02
UroGen Pharma to Participate at Upcoming Investor Conferences	01/02
UroGen Pharma Starts Rolling NDA Submission for Bladder Cancer Drug	24/01
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102	24/01
UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102	24/01
Urogen Pharma Ltd. Enters into A License and Supply Agreement (The Agreement) with Medac Gesellschaft Für Klinische Spezialpräparate m.b.H	17/01
UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024	17/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue UroGen Pharma Ltd.

Azioni

URGN

IL0011407140

Altre lingue

Filtri